Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
Blood Advances|September 2, 2018
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studiesAlexander Röth, Scott T Rottinghaus, Anita Hill, et al.
Annals of Hematology|January 22, 2025
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuriaAustin Kulasekararaj, Robert Brodsky, Hubert Schrezenmeier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2020
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient RegistryYadanar Lwin, Glenn Kennedy, David Gottlieb, et al.
The New England Journal of Medicine|March 17, 2021
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Jeff Szer, Ilene Weitz, et al.
Internal Medicine Journal|March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma AustraliaShirlene Sim, Anna Kalff, Gina Tuch, et al.
Hematology/Oncology and Stem Cell Therapy|June 11, 2019
Special report: Summary of the first meeting of African Blood and Marrow Transplantation (AfBMT) group, Casablanca, Morocco, April 19-21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT)Mhamed Harif, Daniel Weisdorf, Nicolas Novitzky, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2025
Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 TrialMohamad Mohty, Gerard Socié, Jeff Szer, et al.
Blood|June 21, 2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Harry J Iland, Ken Bradstock, Shane G Supple, et al.
The Lancet. Haematology|July 1, 2022
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trialAbby Douglas, Karin Thursky, Timothy Spelman, et al.
Pageof 15